Home / Themes / Stagflation Short '25: Expensive Tech
Stagflation Short '25: Expensive Tech
Last updated
Theme thesis · 3/5 sections · Tickers 5 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsIn the face of Trump's aggressive tariff regime and supply chain realignment, expensive tech—especially hardware-dependent and consumer-exposed names—are struct
Thesis
In the face of Trump's aggressive tariff regime and supply chain realignment, expensive tech—especially hardware-dependent and consumer-exposed names—are structurally vulnerable. These companies sit at the intersection of rising input costs, margin compression, weak global demand, and overvaluation. The assumption that tech is “deflation proof” is proving dangerously wrong.
Bull case
Tariff Exposure & Input Cascade: Hardware costs are compounding through the supply chain; sourcing from Malaysia and Taiwan makes this worse post-April tariff wave.
Demand Weakness + Valuation Risk: Growth multiples are getting hit as discretionary consumer and enterprise budgets stall and rising rates compress terminal values.
“Software” Companies Aren't Safe: NTAP, ZS, and SOUN depend on physical components to deliver services—raising costs and delaying deliverables—while lacking pricing power to offset the inflation.
Bear case
AI/Infrastructure Capex Dominance Persists: Hyperscaler demand and government data center buildouts could continue to pull forward AI-related investment despite macro.
Re-Localization Tailwind is Monetized: Companies like AAPL/DELL that invest in North America manufacturing get ahead of the curve and avoid worst shocks.
Fed Prioritizes Growth Over Inflation Again: Should Powell cut aggressively post-April despite tariffs, it could spark a risk-on rally that favors high-duration growth stocks.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Forward EPS Revision Breadth – Hardware Sector | Weekly | Earnings downgrade momentum in hardware-oriented tech (NVDA, DELL, NTAP) from margin & demand shocks | Google_Sheets |
| U.S. Import Price Index – Computers & Electronics | Monthly | Tariff-driven input cost inflation for tech hardware and device-heavy firms like AAPL, DXCM, PODD | Google_Sheets |
| Enterprise IT Spend Tracker | Quarterly | Capex reallocation or slowdown in enterprise IT spend impacting NTAP, ZS, NVDA | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| NVDA_ce824b94 | Q1 and beyond | 2026-02-01 | 2026-12-31 | Resolution of supply constraints impacting NVIDIA's Gaming segment. | Persistent supply constraints could be a headwind to Gaming revenue growth in fiscal year 2027, potentially impacting overall revenue and investor sentiment for this segment. | Ticker | 2026-02-25 | earnings_transcript | NVDA (ticker) |
| NVDA_cd66c95e | we do not know whether any imports will be allowed into China | 2026-02-25 | 2027-01-31 | U.S. government decision on allowing imports of NVIDIA's H200 or other competitive data center compute products into China, or a change in NVIDIA's ability to generate revenue from China-based customers. | The inability to ship competitive products to China due to export controls and the lack of revenue from this market significantly limits NVIDIA's total addressable market and growth potential, while allowing local competitors to gain ground. | Ticker | 2026-02-25 | earnings_transcript | NVDA (ticker) |
| NVDA_f142a069 | uncertain whether any imports will be allowed into the country. As a result, consistent with last quarter, we are not including any China data center compute revenue in our outlook. | 2026-06-01 | 2027-01-31 | US government allowing imports and NVIDIA generating revenue from H200 shipments to China-based customers. | Generating revenue from China would provide upside to NVIDIA's outlook, which currently excludes this market. Continued restrictions or lack of revenue would remain a bearish overhang. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| NVDA_4bf2c864 | nearly $20 billion in total CPU revenue this year. | 2026-06-01 | 2026-12-31 | NVIDIA achieving its target of nearly $20 billion in standalone Vera CPU revenue for the current calendar year. | This represents NVIDIA's entry into a new $200 billion TAM for agentic AI. Achieving this target would be a strong bullish signal for its CPU strategy and market expansion. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| NVDA_62d4dad4 | we expect supply constraints to be the headwind to Gaming in Q1 and beyond. | 2026-05-01 | 2027-01-31 | Resolution or significant easing of supply constraints impacting NVIDIA's Gaming segment. | Supply constraints are a headwind to Gaming revenue. Resolution would be bullish, allowing for higher sales, while persistence would continue to limit growth. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| NVDA_bed7ea29 | For the full year, we are still expecting to be in the mid seventies. | 2026-02-01 | 2027-01-31 | NVIDIA reporting its full-year fiscal year 2027 non-GAAP gross margin. | Maintaining gross margins in the mid-70s is crucial for profitability given rising input costs and system complexity. Achieving this target would be bullish, while a miss would be bearish. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| NVDA_706e5870 | analysts now forecasting hyperscale CapEx to exceed $1 trillion by 2027 | 2026-06-01 | 2027-12-31 | Hyperscalers' total capital expenditures exceeding $1 trillion by the end of 2027. | This is a key macro driver for NVIDIA's data center business. Achieving this level of spending would be highly bullish for NVIDIA's revenue trajectory, while a slowdown would be bearish. | Theme | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| NVDA_71afbfda | AI infrastructure spending is on track to reach $3 trillion to $4 trillion annually by the end of this decade. | 2026-06-01 | 2029-12-31 | Global AI infrastructure spending reaching $3 trillion to $4 trillion annually by the end of the decade. | This represents the long-term market opportunity for NVIDIA. Progress towards this target would be highly bullish, indicating sustained demand for its AI platforms and validating the 'Intelligence Infrastructure Supercycle' theme. | Theme | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| PODD_3f4381e7 | in the first half of 2026 | 2026-03-01 | 2026-06-30 | Launch of Omnipod 5 integration with FreeStyle Libre 3 Plus continuous glucose monitor (CGM). | This expands Omnipod's compatibility to a major sensor, making it accessible to a broader patient base and potentially increasing market share, impacting demand trajectory and competitive position. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_1dde0925 | In 2026, we will continue to purposely increase R&D investment to advance our next-generation platforms, including Omnipod 6 as well as our fully closed-loop system for type 2 diabetes and future innovations. This also includes continued progress across our clinical programs with ongoing work in STRIVE and EVOLUTION. | 2026-01-01 | 2026-12-31 | Global rollout of Omnipod Discover, a new data platform providing streamlined insights for healthcare professionals and users. | This platform aims to support efficient HCP review, simplify onboarding, and strengthen engagement, potentially improving customer retention and reducing cost to serve, which impacts margins and investor sentiment. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_87e6177c | pivotal data to be presented at ADA in June | 2026-06-01 | 2026-06-30 | Presentation of pivotal results from the STRIVE study for Omnipod 6 at the American Diabetes Association (ADA) conference. | Positive pivotal data is crucial for supporting the regulatory filing and future commercial success of Omnipod 6, demonstrating its advanced features and potential to enhance clinical outcomes and user experience. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_40f7ce65 | We expect to initiate our pivotal EVOLUTION study this year, supporting a regulatory filing in 2027 and a commercial launch in 2028. | 2026-01-01 | 2026-12-31 | Initiation of the pivotal EVOLUTION study for Insulet's fully closed-loop system designed for people with Type 2 diabetes. | This study is a critical step towards regulatory approval and commercialization of a system intended to address a significant unmet need in the large Type 2 diabetes market, potentially transforming Insulet's growth trajectory. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| ZS_86551063 | short term | 2026-05-01 | 2027-04-30 | Resolution of sales leadership transitions and their impact on sales execution and growth trajectory. | The departure of two sales leaders and the ongoing transition could disrupt sales execution, potentially impacting net new ARR growth and overall revenue. Management has already taken a 'prudent approach' to guidance due to this uncertainty. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_a5e0f27c | Q4 | 2026-05-01 | 2027-04-30 | Higher capital expenditures in Q4 FY26 and fiscal year 2027 due to increasing memory, storage, and processor prices, impacting free cash flow margin. | Increased CapEx will negatively impact free cash flow margin in Q4 FY26 and FY27, as reflected in the lowered free cash flow margin guidance for FY26. This could impact profitability and investor sentiment. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_ab629f13 | will have impact in fiscal '27 | 2026-05-01 | 2027-04-30 | Accelerated enterprise adoption of AI and the emergence of powerful frontier AI models driving increased demand for Zscaler's Zero Trust security solutions. | This represents a significant tailwind, potentially boosting pipeline, new logo wins, and upsells for Zscaler's AI Protect and Zero Trust solutions, positively impacting revenue and ARR growth. | Theme | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_8c7cb2dc | in '27 | 2026-05-01 | 2027-04-30 | Rollout and customer uptake of the integrated SecOps solution, combining Zscaler's platform with Red Canary's capabilities. | Successful uptake could drive further upsell and cross-sell opportunities, contributing to ARR growth. The uncertainty around the pace of uptake could impact the realization of this growth. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| ZS_494da17d | an important part of our fiscal '27 plan | 2026-05-01 | 2027-04-30 | Execution and effectiveness of new initiatives to accelerate new logo acquisition, particularly in the mid-market enterprise segment and through channel partners. | Improved new logo growth is a strategic focus and could significantly boost ARR and market share, offsetting the 'tempered view' currently incorporated into FY27 guidance. Failure to execute could further pressure growth. | Ticker | 2026-05-26 | earnings_transcript | ZS (ticker) |
| NVDA_37bbccd7 | second half of the year | 2026-07-01 | 2026-12-31 | Commencement of production shipments for NVIDIA's Vera Rubin platform. | The successful ramp and customer adoption of the Rubin platform are crucial for NVIDIA's continued revenue growth, competitive leadership, and gross margin sustainability, as it offers significant performance improvements over Blackwell. | Ticker | 2026-02-25 | earnings_transcript | NVDA (ticker) |
| NVDA_91d7be67 | second half of this year starting in Q3 | 2026-07-01 | 2027-03-31 | Commencement of production shipments and subsequent ramp of NVIDIA's VeraRubin platform. | VeraRubin is expected to deliver significantly higher inference throughput and AI factory revenue compared to Blackwell, opening a new $200 billion TAM for NVIDIA. A successful ramp is bullish, while delays or production issues would be bearish. | Ticker | 2026-05-20 | earnings_transcript | NVDA (ticker) |
| PODD_4c284f22 | Spain, our newest market, is expected to launch Omnipod 5 later this year. | 2026-07-01 | 2026-12-31 | Commercial launch of Omnipod 5 in Spain, a new international market. | Entry into new geographies is a key component of Insulet's international growth strategy, driving volume and market share gains, which directly impacts revenue and investor sentiment. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| DELL_82b47ca0 | second half of FY2027 | 2026-08-01 | 2027-01-31 | Vera Rubin AI server architecture shipments are expected to begin in production in the second half of FY2027. | A successful Rubin ramp would expand Dell's AI server capacity and address backlog, supporting accelerated AI revenue growth and potential margin expansion as high-value Dell IP storage and optimization benefit mix; delays could temper AI upside and utilization of the five-quarter pipeline. | Ticker | 2026-02-26 | earnings_transcript | DELL (ticker) |
| PODD_5dda514d | supporting a regulatory filing in 2027 | 2027-01-01 | 2027-12-31 | Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes. | Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_93a0b76a | accelerate our innovation cycle as we prepare for launch in 2027 | 2027-01-01 | 2027-12-31 | Commercial launch of Insulet's next-generation Omnipod 6 system. | This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_fdc63d7d | a commercial launch in 2028 | 2028-01-01 | 2028-12-31 | Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes. | This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |
| PODD_55d4bc0d | expected to be operational in 2029 | 2029-01-01 | 2029-12-31 | Insulet's new manufacturing facility in Costa Rica becomes operational. | This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation. | Ticker | 2026-02-18 | earnings_transcript | PODD (ticker) |